受强制性开放获取政策约束的文章 - kalpana tilekar了解详情
无法在其他位置公开访问的文章：8 篇
Discovery of 5-naphthylidene-2, 4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines
K Tilekar, N Upadhyay, N Jänsch, M Schweipert, P Mrowka, ...
Bioorganic chemistry 95, 103522, 2020
强制性开放获取政策： Department of Science & Technology, India
Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy
N Upadhyay, K Tilekar, F Loiodice, NY Anisimova, TS Spirina, ...
Bioorganic Chemistry 107, 104527, 2021
强制性开放获取政策： Department of Science & Technology, India
Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery
K Tilekar, O Shelke, N Upadhyay, A Lavecchia, CS Ramaa
Journal of Molecular Structure 1250, 131767, 2022
强制性开放获取政策： Department of Science & Technology, India
Synthesis and biological evaluation of pyrazoline and pyrrolidine‐2, 5‐dione hybrids as potential antitumor agents
K Tilekar, N Upadhyay, FJ Meyer‐Almes, F Loiodice, NY Anisimova, ...
ChemMedChem 15 (19), 1813-1825, 2020
强制性开放获取政策： Department of Science & Technology, India
Double-edged swords: diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis
N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ...
Bioorganic Chemistry 116, 105350, 2021
强制性开放获取政策： Department of Science & Technology, India, National Medical Research Council …
Recent anti‐angiogenic drug discovery efforts to combat cancer
N Upadhyay, K Tilekar, S Safuan, AP Kumar, J Stalin, C Ruegg, ...
ChemistrySelect 6 (23), 5689-5700, 2021
强制性开放获取政策： Swiss National Science Foundation, Department of Science & Technology, India …
Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2
N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ...
Future medicinal chemistry 13 (22), 1963-1986, 2021
强制性开放获取政策： Department of Science & Technology, India, National Medical Research Council …
Design, in silico studies, synthesis, and in vitro anticancer assessment of new naphthylidene isoxazolidinedione derivatives
N Upadhyay, K Tilekar, A Oak, VS Pokrovsky, R Subramanian Chelakara
Vietnam Journal of Chemistry 62 (2), 217-226, 2024
强制性开放获取政策： Department of Science & Technology, India
可在其他位置公开访问的文章：10 篇
Hantavirus immunology of rodent reservoirs: current status and future directions
T Schountz, J Prescott
Viruses 6 (3), 1317-1335, 2014
强制性开放获取政策： US National Institutes of Health
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer
K Tilekar, N Upadhyay, CV Iancu, V Pokrovsky, J Choe, CS Ramaa
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1874 (2), 188457, 2020
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation
N Upadhyay, K Tilekar, N Jänsch, M Schweipert, JD Hess, LH Macias, ...
Bioorganic chemistry 100, 103934, 2020
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential
K Tilekar, N Upadhyay, JD Hess, LH Macias, P Mrowka, RJ Aguilera, ...
European journal of medicinal chemistry 202, 112603, 2020
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Permuted 2, 4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells
K Tilekar, N Upadhyay, M Schweipert, JD Hess, LH Macias, P Mrowka, ...
European Journal of Pharmaceutical Sciences 154, 105512, 2020
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects
K Tilekar, JD Hess, N Upadhyay, AL Bianco, M Schweipert, A Laghezza, ...
Journal of medicinal chemistry 64 (10), 6949-6971, 2021
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks
N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ...
RSC Medicinal Chemistry 12 (9), 1540-1554, 2021
强制性开放获取政策： Department of Science & Technology, India, National Medical Research Council …
HDAC4 Inhibitors with Cyclic Linker and Non‐hydroxamate Zinc Binding Group: Design, Synthesis, HDAC Screening and in vitro Cytotoxicity evaluation.
K Tilekar, JD Hess, N Upadhyay, M Schweipert, F Flath, DA Gutierrez, ...
ChemistrySelect 6 (26), 6748-6763, 2021
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
Mechanistic insights into binding of ligands with thiazolidinedione warhead to human histone deacetylase 4
M Schweipert, N Jänsch, N Upadhyay, K Tilekar, E Wozny, S Basheer, ...
Pharmaceuticals 14 (10), 1032, 2021
强制性开放获取政策： Department of Science & Technology, India
Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention
N Upadhyay, K Tilekar, JD Hess, VS Pokrovsky, RJ Aguilera, CS Ramaa
Current Research in Chemical Biology 1, 100006, 2021
强制性开放获取政策： US National Institutes of Health, Department of Science & Technology, India
出版信息和资助信息由计算机程序自动确定